Brii Biosciences Limited · HKEX:2137
Brii Biosciences — Investor Presentation (October 2026)
29 slides from Brii Biosciences's investor presentation, October 2026
Slide 1: Corporate Presentation
Stock Code: 2137.HK Corporate Presentation OCTOBER 2026
Slide 2: Disclaimer
Disclaimer This presentation has been delivered for information purposes only and upon the express understanding that recipients of this presentation will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase sec
Slide 3: Who We Are: Building Brii Bio's Next Phase of Growth
Who We Are: Building Brii Bio’s Next Phase of Growth Our Mission Our Focus To address prevalent health conditions with Harnessing the potential of RNA as a significant unmet need through breakthrough platform to develop differentiated scientific innovation and critical patient insights treatment opt
Slide 4: World-class Leadership Team with a Proven Track Record of Success
World-class Leadership Team with a Proven Track Record of Success Corporate Executive Team Haifeng Cao Eleanor (Ellee) de Groot Zhi Hong Head of China Clinical Development Chief Technology Officer Chief Executive Officer Brian A. Johns Ankang Li David Margolis Chief Scientific Officer Chief Operatin
Slide 5: Board of Directors and Strategic Advisors
World-class Leadership Team with a Proven Track Record of Success Board of Directors Zhi Hong Ankang Li Martin J. Murphy, Jr. Grace Hui Tang Yiu Wa Alec Tsui Gregg Huber Alton Taiyin Yang Executive Director Executive Director Independent Independent Independent Independent Independent Non-executive
Slide 6: Brii Bio's Pipeline
Brii Bio’s Pipeline Indication Program Modality Discovery Preclinical Phase 1 Phase 2 Phase 3 BRII-179 Therapeutic vaccine HBV Cure Elebsiran(1) siRNA BRII-8919 Undisclosed HDV Elebsiran + Tobevibart(1,2) siRNA + mAb HBV+ HCC BRII-5395 mRNA MDR Soralimixin(3) Cyclic Peptide BRII-732 Once-weekly oral
Slide 7: HBV: Road to Cure
HBV Road to Cure
Slide 8: China Is the Largest Market for HBV Functional Cure
China Is the Largest Market for HBV Functional Cure Large Addressable Patient Population High Unmet Need for New Therapy Options No new novel MoAs have been approved in over 20 years Number of HBV USD expected for the ~240M Infected People ~3.4B China HBV market by Current SOC consisting of NRTIs or
Slide 9: The Natural History of Chronic HBV Infection Is Complex
The Natural History of Chronic HBV Infection Is Complex Leaving HBV Patients at Different Stages of Disease and Underlying Immune Impairment Active hepatitis, reactivation and hepatitis flares significantly increase the risk of developing cirrhosis and hepatocellular carcinoma (HCC) HBeAg+ HBeAg- an
Slide 10: Novel Combination Therapies May Lead to Higher Functional Cure Rates
Novel Combination Therapies May Lead to Higher Functional Cure Rates Across All HBV Patient Groups Antiviral and immunomodulation are critical targets for successful HBV therapy Reduction of viral antigen / genomic products Goal of New Therapies – HBV Functional Cure: ✓ Sustained, undetectable serum
Slide 11: Brii Bio's Programs for HBV Functional Cure Focus on Unique Mechanisms
Brii Bio’s Programs for HBV Functional Cure Focus on Unique Mechanisms of Action for Both Host and Viral Pathways BRII-179 Host Pathways Innate Immune Responses Adaptive Immune Responses Optimized Recombinant Virus-like Particle (VLP)-Based Vaccine NK Cells, other Innate B Cells, CD4+, Immune Cells
Slide 12: Brii Bio's HBV Functional Cure Program Overview
Brii Bio’s HBV Functional Cure Program Overview A growing body of clinical data supporting Brii Bio’s functional cure strategy Registered Clinical Trials Phase 1 Phase 2 Phase 3 Elebsiran + BRII-179 BRII-179 + PEG-IFNα ENSURE (elebsiran + PEG-IFNα vs PEG-IFNα) ENRICH (BRII-179 → elebsiran + PEG-IFNα
Slide 13: Therapeutic Vaccine BRII-179 Induced Strong Anti-HBs Responses
64001-003 65001-001 66002-002 66001-001 Therapeutic Vaccine BRII-179 Induced Strong Anti-HBs Responses Are 66003-001 82001-001 82002-001 82003-002 Associated with Pre-S1/S2-Specific CD4 T-cell Responses 82003-003 85201-002 85203-001 85203-003 85203-004 88605-001 Anti-HBs production is associated wit
Slide 14: ENSURE Study: Functional Cure Reached 36.8% in BRII-179 Responders
ENSURE Study: Functional Cure Reached 36.8% in BRII-179 Responders STUDY WEEK 00 12 24 36 48 60 72 NRTl Treatment PEG-IFNα QW Follow-up Cohorts 1-3 BRII-179 naïve with Elebsiran 200 mg Q4W + PEG-IFNα QW Follow-up baseline HBsAg 24-Week NRTI 100-3,000 IU/mL Discontinuation Elebsiran 100 mg Q4W + PEG-
Slide 15: ENRICH Study: Prospectively Evaluating the Priming Effect of BRII-179
ENRICH Study: Prospectively Evaluating the Priming Effect of BRII-179 HBsAg Loss at EOT Baseline HBsAg 100-3,000 IU/mL 50% 41.9% 42.9% 40.0% Key Takeaways 40% 29.7% • Higher HBsAg loss following BRII-179 30% pretreatment was reproduced across three cohorts 20% • The non-primed ENSURE Cohorts 2&3 HBs
Slide 16: ENHANCE Study: Preliminary HBsAg Loss Results at EOT
ENHANCE Study: Preliminary HBsAg Loss Results at EOT Data cut STUDY WEEK 00 12 24 36 48 56 64 72 HBsAg Loss At EOT NRTI Treatment Part A1 BRII-179 + Elebsiran + PEG-IFN BRII-179 + elebsiran + 25.5% Follow-up PEG-IFNα (A1) (25/98) Combination treatment PEG-IFN PEG-IFNα 10.2% (5/49) Part A2 NRTI Tre
Slide 17: Discovery: Driving Continuous Innovation
Discovery Driving Continuous Innovation
Slide 18: BRiSC (Bispecific RNAi SilenCing)
BRiSCTM (Bispecific RNAi SilenCing) Engineering siRNA Medicines Beyond Conventional Limits An integrated suite of technologies designed to expand the therapeutic potential of siRNA medicines through sequence engineering, advanced chemistry, multi-target design, and enhanced tissue delivery capabilit
Slide 19: Addressing Metabolic Dysfunctions & Comorbidities
Addressing Metabolic Dysfunctions & Comorbidities One Molecule. Two Targets. Complex biology and overlapping comorbidities create an opportunity for coordinated therapeutic intervention Addressing complexity Simplifying treatment Targeting distinct Delivering dual targeted mechanisms underlying phar
Slide 20: Increasing Early Discovery Efforts to Fuel Brii Bio's Future
Increasing Early Discovery Efforts to Fuel Brii Bio’s Future Expanding discovery team of experienced Building a Sustainable Engine for scientists Internal Innovation ✓ Sustained investment in internal discovery capabilities is translating into a growing portfolio of internally discovered drug candid
Slide 21: HIV: Long-Acting Treatment Options
HIV Long-Acting Treatment Options
Slide 22: Daily Oral Market Expected To Shift To Long-Acting Options
Daily Oral Market Expected To Shift To Long-Acting Options as New Therapies Become Available Global Market Will Continue to Increase(1) High Unmet Need for Long-Acting Therapy Options • Global HIV market reached $41.2 billion in 2025 • Developed markets, such as the United States, currently Patient
Slide 23: Developing Long-Acting Oral and Injectable Formulations of ISL Prodrug
Brii Bio is Developing Long-Acting Oral and Injectable Formulations of ISL Prodrug to be Combined with Other MoAs Building a Long-Acting HIV Therapy Portfolio NRTI: nucleoside reverse transcriptase inhibitor • BRII-732 is an oral NCE with completed BRII-732/787 NRTTI: nucleoside reverse transcriptas
Slide 24: BRII-732 and BRII-787 are Ideal Cornerstones for Next Generation HIV Therapies
BRII-732 and BRII-787 are Ideal Cornerstones for Next Generation HIV Therapies Ideal Backbone for Once-Weekly Oral & Twice-Yearly Injectable Combinations: Capsid Inhibitor 3 2 1 BRII-732 OR MoAs Drugs Injection + NNRTI or Tablet or OR Long- NRTI, BRII-732/787, Integrase Inhibitor BRII-787 OR NRTTI,
Slide 25: Antibiotic Resistance
Antibiotic Resistance Mitigating a Major Public Health Threat
Slide 26: Soralimixin Is Designed to Address Critical Limitations of Existing Polymyxins
Soralimixin Is Designed to Address Critical Limitations of Existing Polymyxins WHO Priority #1 List for New Drugs Unmet Needs for Gram-Negative Bacterial Infections(1) ➢ Very limited choices of antibiotics to treat carbapenem-resistant Acinetobacter spp. and P. aeruginosa, particularly for criticall
Slide 27: Soralimixin is a Potent and Safer New-Generation Polymyxin
Soralimixin is a Potent and Safer New-Generation Polymyxin • Soralimixin (BRII-693) is a synthetic polymyxin Carbapenem-resistant Acinetobacter spp (N=503)(1) systematically optimized at multiple non-conserved 300 Number of Isolates BRII-693 Colistin positions and demonstrates a combination of incre
Slide 28: Upcoming Catalysts Across Our Expanding Pipeline
Upcoming Catalysts Across Our Expanding Pipeline ❑ Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026 • Preclinical data for BRII-5395 ❑ American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026 • Additional data from the ENRICH and ENHANCE studies ❑ 1H 2027 • I
Slide 29: Thank You!
Stock Code: 2137.HK Thank You!
Brii Biosciences — Investor Presentation (October 2026) on 6ix